Barron's Interview Stephen Pesek
528 views
Rate Now: 1 2 3 4

average rating: 0.00 / 0 ratings
Created by barrons3
DESCRIPTION:

Date updated:11-01-2008

Talking With Stephen Pesek, Portfolio Manager, MFS Core Growth Fund.

symbol name last price % change open
  • +
  • AAPL
    Apple Inc.
  • $93.02
  • -1.65%
  • $95.96

His top holdings include many electronics outfits (he once ran an electronics fund for Fidelity), such as Apple (AAPL), Cisco Systems (CSCO) and IBM (IBM), all of which have suffered big price drops in the downdraft created by the credit crisis. That doesn't faze him because he invests with at least an 18-month time horizon.

People owning AAPL also tend to own: AMDCSCODELLGOOGIBMINTCMSFT

TheStreet.com Rating: C+ What is this?

  • +
  • CSCO
    Cisco Systems
  • $17.79
  • +3.97%
  • $17.35

His top holdings include many electronics outfits (he once ran an electronics fund for Fidelity), such as Apple (AAPL), Cisco Systems (CSCO) and IBM (IBM), all of which have suffered big price drops in the downdraft created by the credit crisis. That doesn't faze him because he invests with at least an 18-month time horizon.

People owning CSCO also tend to own: AAPLAMDDELLGOOGIBMINTCMSFT

TheStreet.com Rating: C What is this?

  • +
  • IBM
    Intl Business Mac
  • $89.23
  • +2.78%
  • $87.11

His top holdings include many electronics outfits (he once ran an electronics fund for Fidelity), such as Apple (AAPL), Cisco Systems (CSCO) and IBM (IBM), all of which have suffered big price drops in the downdraft created by the credit crisis. That doesn't faze him because he invests with at least an 18-month time horizon.

People owning IBM also tend to own: AAPLAMDCSCODELLGOOGINTCMSFT

TheStreet.com Rating: C+ What is this?

  • +
  • ORCL
    Oracle Corporatio
  • $18.39
  • +1.66%
  • $18.28

Although Oracle, like every vendor, is under pressure to provide discounts, he thinks it can gain share in a downturn and still expand margins. "They can control their own destiny," Pesek says, because the company is dominant in database software, with a 49% share, up from 39% five years ago. What's more, it's been a very active buyer of applications businesses such as Prima-vera, Hyperion and BEA. Oracle "is a little bit controversial in terms of organic versus acquired growth, but the company has a visible margin-expansion path," Pesek explains. The Street puts Oracle's earnings per share at $1.50 in '09 and $1.68 in '10. He added to his Oracle position last spring when it was in the high teens to low 20s. Oracle was recently trading near the bottom of its 52-week range at $18.32 a share, or less than 12 times 2009 earnings projections.

People owning ORCL also tend to own: AAPLAMDCSCODELLGOOGIBMINTC

TheStreet.com Rating: B What is this?

  • +
  • GENZ
    Genzyme Corporati
  • $66.19
  • -2.23%
  • $68.34

Pesek also likes Cambridge, Mass.-based Genzyme (GENZ), a biotech outfit focused on diseases stemming from enzyme disorders. "Its small nichey markets provide an opportunity to raise prices," Pesek says, noting that many of its pipeline products -- such as Myozyme, for treating often-fatal Pompe disease, which can affect muscles and the heart, and Mozibil, used to increase stem-cell counts in transplants -- benefit from orphan-drug status. Campath, for multiple sclerosis, differs because it has a potentially enormous market. The National MS Society estimates that about 200 Americans are diagnosed with this auto-immune disease every week. Overall, there are about 400,000 people in the U.S. and more than 2.5 million people worldwide suffering from MS. "Management believes they can achieve a compound annual growth rate in earnings per share of 20% from 2007-2010, and if pipeline products are successful that will be even better," Pesek says. He added to his Genzyme stake in the summer of 2007 when the stock was trading in the low to mid-60s. More recently, it's been trading at 70.20. The consensus estimate for Genzyme's EPS is $3.97 in '08, $4.73 in '09 and $5.55 in '10. Its price-to-earnings multiple works out to about 15 times '09 estimates.

People owning GENZ also tend to own: LRCXWRLDAMGNDNAAMZNBLUDHPQ

TheStreet.com Rating: B- What is this?

  • +
  • CVS
    Cvs Caremark Cp
  • $29.35
  • -1.51%
  • $30.00

He thinks CVS Caremark (CVS) is undervalued because it sells at 11 times 2009 EPS, versus an average of 15 times for pharmacy benefits-management plays generally. He notes that half the Woonsocket, R.I.-based company's earnings come from this benefits-management portion of the business, which can play an important role in controlling the country's drug costs. Return on invested capital is improving, and the company's business mix has been remarkably resilient over time, says Pesek. He began buying in the summer of 2007, when it was in the mid-30s. It has since dropped to below 25, but he sees good potential for growth, since it has about a 18% share of the prescriptions written in the U.S. That's below Walgreens' and mail-order's share but represents a rising portion compared to independent outlets. CVS' earnings are expected to be $2.46 a share in '08, $2.77 in '09 and $3.19 in '10.

People owning CVS also tend to own: ADMAVPBF-BBTICLDEOK

TheStreet.com Rating: C+ What is this?

  • +
  • GDNNY.PK
    Groupe Danone Ads
  • $12.22
  • +0.25%
  • $12.03

Core Growth Fund is run on a fundamental, bottom-up basis and mostly eschews the macro environment in making investment decisions. However, Pesek does think that people will eat at home more as the economy cools, and he's recently bought Groupe Danone SA (BN.France), the French food company, as a potential beneficiary of that trend. Danone, he notes, has a 36% share of the yogurt market, which has grown in the 4% to 10% range in recent years. And falling commodity prices could aid margins. Danone has also gotten into the baby-food business via an acquisition. Pesek says Danone has a mid- to high-teens EPS growth rate, yet a lower than average valuation versus European peers that aren't growing as fast. And Danone has a rising return on invested capital. The Danone position was built up last summer and added to in the spring of 2008, when it was in the high 40s to low 50s euros. The share price, recently at 43 euros, hasn't gone anywhere, but EPS projections of €2.77 in '08, €3.12 in '09, and €3.54 in '10 would give it a P/E of roughly 14 times 2009 earnings. And that's just the sort of stock that appeals to Pesek, especially in scary times.

People owning GDNNY.PK also tend to own: BBYBWLDBXCAKECLWREWSRL

TheStreet.com Rating: No Rating What is this?

Portfolio not tracked!

Comments not available

ADD YOUR COMMENTS:

Short This Stock Ahead of Earnings

As consumer spending grinds to a complete halt amid the worst economic slowdown since the Great Depression, it is certainly surprising to see some companies dependent on di...

01.07.09 | 11:27 AM
Top Nasdaq Short-Squeeze Plays

Many stocks were beaten down at the end of the year from tax-selling, causing many Nasdaq stocks to be depressed. Now that the tax-selling is over, short-sellers might star...

01.06.09 | 17:39 PM
Cramer's Take on Top-Searched St...

After some disappointing news about factory orders and the residential real estate industry, stocks rose moderately on Tuesday, led by Citigroup (C), Bank of America (BAC),...

01.06.09 | 17:13 PM
Chart Smarts: Test Your Market S...

As we transition into 2009, RealMoney.com’s Dan Fitzpatrick continues to cover the charts on stock picks he's found on TV and TheStreet.com. Here’s a look at some po...

01.06.09 | 11:17 AM
more articles
General market Technical Analysi...
11.14.07 | 22:55 PM From author ZackAttack
The Presidential/Political Thread
01.02.08 | 08:05 AM From author Dave Cox
Post your #1 pick for 2009
12.31.08 | 10:19 AM From author Momentumseeker
A truly phenomenal trader, Jan E...
12.31.08 | 02:09 AM From author best_traders
more forums
Q. Goldman Sachs Group Inc. (GS)......
01.07.09 | 15:11 PM Asked by π

A. "...i was wong, but hold them..."

wow...that does not sound good...that
makes me wonder about your strategy in
the historical market that we are
experiencing.

today 's lists
Stocks Most Likely to Surprise

This list consists of stocks that are down 10% or more in the last year but may be poised to surprise us on the upside going forward. The basis for the list is as follows: ... more

Rising on Unusual Volume

Here are some stocks that moved up on unusual volume on Jan. 6, 2009. more

Upcoming Stock Splits

This list consists of stocks with upcoming splits. It will be updated every 2 weeks. more